BioGenes and Eurofins BioPharma Product Testing Munich
News Jun 04, 2016
BioGenes GmbH, a global leader in host cell protein (HCP) assay development, has entered into a collaboration with Eurofins BioPharma Product Testing Munich (Eurofins Munich), an internationally renowned Contract Research Organization for (bio)pharmaceutical product-testing and Centre of Excellence for Bioassays, to serve as its preferred partner for HCP related impurity testing.
BioGenes will provide generic 360-HCP kits and specific HCP assay development services as well as related 2D electrophoresis (2D-DIGE) and concomitant antibody preparation. Eurofins Munich will provide complementary analytical services to BioGenes spanning the complete product development cycle from lead discovery to late stage clinical development.
Eurofins BioPharma Product Testing Munich GmbH, in cooperation with BSL Bioservice Scientific Laboratories Munich GmbH, supports its clients especially in the fields of bioassays, microbiology, in vitro toxicology, pharmacology, and biocompatibility. Immunoanalytical and bioanalytical studies are offered as support of non-clinical and clinical programs. Eurofins BioPharma Product Testing covers the whole range from standardized tests to special requirements and tailor-made studies.
With a strong dedication to quality and customer service since its foundation in 1992, BioGenes is the trusted and experienced immunoassay expert and a well-respected partner for leading pharmaceutical and biotech companies worldwide.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer’s disease, opening the door to development of a drug that could be administered before age 40, and taken for life, to potentially prevent the disease in 50 to 80 percent of at-risk adults.READ MORE